Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

boehringer ingelheim animal health australia pty. ltd. - feline calicivirus - inactivated; feline panleucopenia virus - inactivated; feline rhinotracheitis virus - inactivated; amphotericin; neomycin; polymyxin b; thiomersal - misc. vaccines or anti sera - feline calicivirus - inactivated vaccine-viral active 0.0 ml; feline panleucopenia virus - inactivated vaccine-viral active 0.0 ml; feline rhinotracheitis virus - inactivated vaccine-viral active 0.0 ml; amphotericin antibiotic other 0.0 ml; neomycin antibiotic other 0.0 ml; polymyxin b antibiotic other 0.0 ml; thiomersal mercury other 0.0 ml - immunotherapy - cat - over 8 weeks of age - feline calicivirus | feline enteritis | feline rhinotracheitis | calicivirus (feline) | enteritis (feline) | fcv | feline herpesvirus type 1 | feline infectious enteritis | feline panleucopenia (fp) | fhv-1 | fvr | herpesvirus 1 (feline) | herpesvirus type 1 (feline) | panleucopenia (feline) | rhinotracheitis (feline)

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

boehringer ingelheim animal health australia pty. ltd. - feline calicivirus - inactivated; chlamydophilia felis inactivated; feline leukaemia virus - inactivated; feline panleucopenia virus - inactivated; feline rhinotracheitis virus - inactivated; amphotericin; neomycin; polymyxin b; thiomersal - misc. vaccines or anti sera - feline calicivirus - inactivated vaccine-viral active 0.0 p; chlamydophilia felis inactivated vaccine-viral active 0.0 p; feline leukaemia virus - inactivated vaccine-viral active 0.0 p; feline panleucopenia virus - inactivated vaccine-viral active 0.0 p; feline rhinotracheitis virus - inactivated vaccine-viral active 0.0 p; amphotericin antibiotic other 0.32 ug/ml; neomycin antibiotic other 4.0 ug/ml; polymyxin b antibiotic other 14.0 iu/ml; thiomersal mercury other 18.0 ug/ml - immunotherapy - cat - over 8 weeks of age - feline calicivirus | feline chlamydia psittaci | feline enteritis | feline leukaemia virus | feline rhinotracheitis | calicivirus (feline) | disease caused by | enteritis (feline) | fcv | feline herpesvirus type 1 | feline infectious enteritis | feline panleucopenia (fp) | fhv-1 | fvr | herpesvirus 1 (feline) | herpesvirus type 1 (feline) | panleucopenia (feline) | rhinotracheitis (feline)

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

boehringer ingelheim animal health australia pty. ltd. - feline calicivirus - inactivated; chlamydophilia felis inactivated; feline panleucopenia virus - inactivated; feline rhinotracheitis virus - inactivated; amphotericin; neomycin; polymyxin b; thiomersal - misc. vaccines or anti sera - feline calicivirus - inactivated vaccine-viral active 0.0 p; chlamydophilia felis inactivated vaccine-viral active 0.0 p; feline panleucopenia virus - inactivated vaccine-viral active 0.0 p; feline rhinotracheitis virus - inactivated vaccine-viral active 0.0 p; amphotericin antibiotic other 1.36 ug/ml; neomycin antibiotic other 12.0 ug/ml; polymyxin b antibiotic other 20.0 iu/ml; thiomersal mercury other 68.0 ug/ml - immunotherapy - cat - over 8 weeks of age - feline calicivirus | feline chlamydia psittaci | feline enteritis | feline rhinotracheitis | vaccine | calicivirus (feline) | enteritis (feline) | equine rotavirus | fcv | feline herpesvirus type 1 | feline infectious enteritis | feline panleucopenia (fp) | fhv-1 | fvr | herpesvirus 1 (feline) | herpesvirus type 1 (feline) | panleucopenia (feline) | rhinotracheitis (feline)

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

boehringer ingelheim animal health australia pty. ltd. - feline immunodeficiency virus(petaluma strain)inactive; neomycin; polymyxin b; thiomersal - misc. vaccines or anti sera - feline immunodeficiency virus(petaluma strain)inactive vaccine-virus active 0.0 p; neomycin antibiotic other 0.0 undefined; polymyxin b antibiotic other 0.0 undefined; thiomersal mercury other 0.0 undefined - immunotherapy - cat - over 8 weeks of age - fiv immunisation

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

boehringer ingelheim animal health australia pty. ltd. - chlamydophilia felis baker strain - live, attenuated; amphotericin b; neomycin; polymyxin b; thiomersal - misc. vaccines or anti sera - chlamydophilia felis baker strain - live, attenuated vaccine-viral active 0.0 p; amphotericin b antibiotic other 1.6 ug/ml; neomycin antibiotic other 24.0 ug/ml; polymyxin b antibiotic other 30.0 iu/ml; thiomersal mercury other 40.0 ug/ml - immunotherapy - cat - over 8 weeks of age | kitten | young cat - feline chlamydia psittaci

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

boehringer ingelheim animal health australia pty. ltd. - amphotericin b; neomycin; polymixin b; feline leukaemia virus - inactivated; thiomersal - misc. vaccines or anti sera - amphotericin b antibiotic active 0.0 undefined; neomycin antibiotic active 0.0 undefined; polymixin b antibiotic active 0.0 undefined; feline leukaemia virus - inactivated vaccine-viral active 0.0 undefined; thiomersal mercury other 0.0 undefined - immunotherapy - cat | cat - queen | cat - tom | kitten - feline leukaemia virus | disease caused by

United States - English - NLM (National Library of Medicine)

marlex pharmaceuticals inc - felbamate (unii: x72rbb02n8) (felbamate - unii:x72rbb02n8) - felbamate 400 mg - felbamate tablets, usp are not indicated as a first line antiepileptic treatment (see warnings ). felbamate tablets, usp are recommended for use only in those patients who respond inadequately to alternative treatments and whose epilepsy is so severe that a substantial risk of aplastic anemia and/or liver failure is deemed acceptable in light of the benefits conferred by its use. if these criteria are met and the patient has been fully advised of the risk, and has provided written acknowledgment, felbamate tablets, usp can be considered for either monotherapy or adjunctive therapy in the treatment of partial seizures, with and without generalization, in adults with epilepsy and as adjunctive therapy in the treatment of partial and generalized seizures associated with lennox-gastaut syndrome in children. felbamate tablets, usp are contraindicated in patients with known hypersensitivity to felbamate, usp, its ingredients, or known sensitivity to other carbamates. it should not be used in patients with a history

United States - English - NLM (National Library of Medicine)

amneal pharmaceuticals llc - felbamate (unii: x72rbb02n8) (felbamate - unii:x72rbb02n8) - felbamate 400 mg - felbamate tablets, usp are not indicated as a first line antiepileptic treatment (see warnings ). felbamate tablets, usp are recommended for use only in those patients who respond inadequately to alternative treatments and whose epilepsy is so severe that a substantial risk of aplastic anemia and/or liver failure is deemed acceptable in light of the benefits conferred by its use. if these criteria are met and the patient has been fully advised of the risk, and has provided written acknowledgment, felbamate tablets, usp can be considered for either monotherapy or adjunctive therapy in the treatment of partial seizures, with and without generalization, in adults with epilepsy and as adjunctive therapy in the treatment of partial and generalized seizures associated with lennox-gastaut syndrome in children. felbamate tablets, usp are contraindicated in patients with known hypersensitivity to felbamate, usp, its ingredients, or known sensitivity to other carbamates. it should not be used in patients with a history of any blood dyscrasia or hepatic dysfunction. abuse: abuse potential was not evaluated in human studies. dependence: rats administered felbamate orally at doses 8.3 times the recommended human dose 6 days each week for 5 consecutive weeks demonstrated no signs of physical dependence as measured by weight loss following drug withdrawal on day 7 of each week.

United States - English - NLM (National Library of Medicine)

aurobindo pharma limited - felodipine (unii: ol961r6o2c) (felodipine - unii:ol961r6o2c) - felodipine 2.5 mg - felodipine extended-release tablets, usp are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including felodipine. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than 1 drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. the largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmhg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). these considerations may guide selection of therapy. felodipine extended-release tablets, usp may be administered with other antihypertensive agents. felodipine extended-release tablets are contraindicated in patients who are hypersensitive to this product.

United States - English - NLM (National Library of Medicine)

impax generics - felbamate (unii: x72rbb02n8) (felbamate - unii:x72rbb02n8) - felbamate 400 mg - felbamate tablets, usp are not indicated as a first line antiepileptic treatment (see warnings ). felbamate tablets, usp are recommended for use only in those patients who respond inadequately to alternative treatments and whose epilepsy is so severe that a substantial risk of aplastic anemia and/or liver failure is deemed acceptable in light of the benefits conferred by its use. if these criteria are met and the patient has been fully advised of the risk, and has provided written acknowledgement, felbamate tablets, usp can be considered for either monotherapy or adjunctive therapy in the treatment of partial seizures, with and without generalization, in adults with epilepsy and as adjunctive therapy in the treatment of partial and generalized seizures associated with lennox-gastaut syndrome in children. felbamate is contraindicated in patients with known hypersensitivity to felbamate, its ingredients, or known sensitivity to other carbamates. it should not be used in patients with a history of any blood dysc